Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2006; 12(45): 7337-7340
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7337
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7337
Table 1 Ratio of cut-off value and optical density (A450 nm) of the sample (or Co/S)
Co/S | Interpretation |
< 0.9 | Negative |
0.9-1.1 | Equivocal |
> 1.1 | Positive |
Table 2 Rate of seroconversion in patients and controls 1 and 6 mo after 1st dose and 1 mo after 2nd dose of HA vaccine
Time | Patients(n = 11) | Controls(n = 13) | P |
n (%) | n (%) | ||
1 mo after the 1st dose of HA vaccine | |||
Positive | 7 (63.6) | 13 (100) | 0.07 |
Equivocal | 2 (18.2) | 0 | |
Negative | 2 (18.2) | 0 | |
6 mo after the 1st dose of HA vaccine | |||
Positive | 7 (63.6) | 13 (100) | 0.09 |
Equivocal | 3 (27.3) | 0 | |
Negative | 1 (9.1) | 0 | |
1 mo after the 2nd (booster) dose of HA vaccine | |||
Positive | 11 (100) | 13 (100) | 0.63 |
Equivocal | 0 | 0 | |
Negative | 0 | 0 |
Table 3 Comparison of the mean value of seroconversion (Co/S) between patients and controls
Time | Patients (n = 11) | Controls (n = 13) | ||
Range | Mean ± SD | Range | Mean ± SD | |
1 mo after the 1st dose of HA vaccine | 0.6-1.6 | 1.1 ± 0.4 | 1.5-3.6 | 2.5 ± 0.97 |
6 mo after the 1st dose of HA vaccine | 0.9-4.8 | 3 ± 1.3 | 2.3-6.9 | 4.7 ± 1.8 |
1 mo after the 2nd (booster) dose of HA vaccine | 3.2-5.3 | 4.6 ± 0.8 | 4.2-5.7 | 4.9 ± 0.7 |
P | bP = 0.003 | aP = 0.02 |
Table 4 Comparison of liver function tests before and after vaccination
Before vaccination | After vaccination | P | |||
Range | Median | Range | Median | ||
Patients | |||||
Total Serum Bilirubin (mg/L) | 4-210 | 7 | 3-250 | 7.5 | 9.5 |
ALT (IU/L) | 19-163 | 42 | 19-136 | 27.5 | 0.11 |
AST (IU/L) | 28-299 | 38 | 30-288 | 43 | 0.07 |
Controls | |||||
Total Serum Bilirubin (mg/L) | 3-6 | 5 | 1-6 | 4 | 4.8 |
ALT (IU/L) | 9-21 | 18 | 10-27 | 17 | 0.93 |
AST (IU/L) | 21-39 | 27 | 21-57 | 31 | 0.01b |
Table 5 Comparison of differences in liver functions before and after vaccination between patients and controls (mean ± SD)
Bilirubin (mg/L) | ALT (IU/L) | AST (IU/L) | |
Patients | 0.8 ± 17 | -11.3 ± 26 | 14.8 ± 23.8 |
Controls | -0.18 ± 0.9 | 0.54 ± 7.3 | 5.1 ± 6.8 |
P | 0.92 | 0.03a | 0.58 |
- Citation: El-Karaksy HM, El-Hawary MI, El-Koofy NM, El-Sayed R, El-Raziky MAS, Mansour SA, Taha GM, El-Mougy F. Safety and efficacy of hepatitis A vaccine in children with chronic liver disease. World J Gastroenterol 2006; 12(45): 7337-7340
- URL: https://www.wjgnet.com/1007-9327/full/v12/i45/7337.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i45.7337